dihydroxyphenylalanine has been researched along with Parkinson Disease, Secondary in 82 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Transient exposure to the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome resembling idiopathic parkinsonism (IP)." | 3.69 | Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. ( Calne, DB; Langston, JW; Schulzer, M; Snow, BJ; Tetrud, JW; Vingerhoets, FJ, 1994) |
| "Susceptibility to Parkinson's disease (PD) is believed to involve an interaction between genetic and environmental factors." | 1.51 | The role of exposure to pesticides in the etiology of Parkinson's disease: a ( Djaldetti, R; Greenbaum, L; Lorberboym, M; Poewe, W; Rigbi, A; Roditi, Y; Scherfler, C; Steinmetz, A, 2019) |
| " We retrospectively analyzed data from 17 stable HP rhesus monkeys treated long-term with chronic intermittent dosing of levodopa (LD) in an attempt to induce choreoathetoid and dystonic dyskinesias." | 1.37 | Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys. ( Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T, 2011) |
| "Parkinsonism without dystonia has been reported in several older members of families with DRD." | 1.29 | Clinical heterogeneity of dopa-responsive dystonia: PET observations. ( Calne, DB; Nygaard, TG; Snow, BJ; Takahashi, H, 1993) |
| "Two patients with Parkinson's disease who underwent implantation of fetal mesencephalic tissue into the putamen were serially studied using positron emission tomography and [18F]6-L-fluorodopa ([18F]dopa)." | 1.28 | Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. ( Björklund, A; Bloomfield, PM; Brooks, DJ; Brundin, P; Leenders, KL; Lindvall, O; Marsden, CD; Rehncrona, S; Sawle, GV; Widner, H, 1992) |
| "To investigate the relation between "on-off" fluctuations in symptomatology and bioavailability of dopa in patients with Parkinson's disease, five Parkinsonian patients with pronounced "on-off" symptoms were studied." | 1.27 | "On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma. ( Carlsson, A; Eriksson, T; Granérus, AK; Linde, A; Magnusson, T, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 50 (60.98) | 18.7374 |
| 1990's | 25 (30.49) | 18.2507 |
| 2000's | 2 (2.44) | 29.6817 |
| 2010's | 5 (6.10) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Djaldetti, R | 1 |
| Steinmetz, A | 1 |
| Rigbi, A | 1 |
| Scherfler, C | 1 |
| Poewe, W | 2 |
| Roditi, Y | 1 |
| Greenbaum, L | 1 |
| Lorberboym, M | 1 |
| Kanazawa, M | 1 |
| Ohba, H | 1 |
| Harada, N | 1 |
| Kakiuchi, T | 1 |
| Muramatsu, S | 1 |
| Tsukada, H | 1 |
| Becker, G | 1 |
| Bahri, MA | 1 |
| Michel, A | 1 |
| Hustadt, F | 1 |
| Garraux, G | 1 |
| Luxen, A | 1 |
| Lemaire, C | 1 |
| Plenevaux, A | 1 |
| Lieu, CA | 1 |
| Deogaonkar, M | 1 |
| Bakay, RA | 1 |
| Subramanian, T | 1 |
| Kita, H | 1 |
| Kita, T | 1 |
| Eriksson, T | 1 |
| Magnusson, T | 1 |
| Carlsson, A | 3 |
| Linde, A | 1 |
| Granérus, AK | 1 |
| Lang, AE | 1 |
| Tranchant, C | 1 |
| Ruh, D | 1 |
| Warter, JM | 1 |
| Cordes, M | 1 |
| Richard, MG | 1 |
| Bennett, JP | 1 |
| Vingerhoets, FJ | 1 |
| Snow, BJ | 3 |
| Tetrud, JW | 1 |
| Langston, JW | 2 |
| Schulzer, M | 1 |
| Calne, DB | 4 |
| Miletich, RS | 1 |
| Comi, G | 1 |
| Bankiewicz, K | 1 |
| Plunkett, R | 1 |
| Adams, R | 1 |
| Di Chiro, G | 1 |
| Kopin, IJ | 2 |
| Takahashi, H | 1 |
| Nygaard, TG | 1 |
| Okada, A | 1 |
| Nakamura, K | 1 |
| Bhatt, MH | 1 |
| Nomoto, M | 1 |
| Osame, M | 1 |
| Burn, DJ | 1 |
| Brooks, DJ | 4 |
| Miyagi, Y | 1 |
| Morioka, T | 1 |
| Otsuka, M | 2 |
| Fukui, M | 1 |
| Hume, SP | 1 |
| Lammertsma, AA | 1 |
| Myers, R | 1 |
| Rajeswaran, S | 1 |
| Bloomfield, PM | 2 |
| Ashworth, S | 1 |
| Fricker, RA | 1 |
| Torres, EM | 1 |
| Watson, I | 1 |
| Jones, T | 1 |
| Katayama, Y | 1 |
| Schneider, JS | 2 |
| Leff, SE | 1 |
| Rendahl, KG | 1 |
| Spratt, SK | 1 |
| Kang, UJ | 1 |
| Mandel, RJ | 1 |
| Doudet, DJ | 2 |
| Chan, GL | 1 |
| Holden, JE | 1 |
| McGeer, EG | 1 |
| Aigner, TA | 1 |
| Wyatt, RJ | 1 |
| Ruth, TJ | 2 |
| Rudnicki, SA | 1 |
| Harik, SI | 1 |
| Dhodapkar, M | 1 |
| Barlogie, B | 1 |
| Eidelberg, D | 1 |
| Fernández-Ruiz, J | 1 |
| Doudet, D | 1 |
| Aigner, TG | 2 |
| Poyot, T | 1 |
| Condé, F | 1 |
| Grégoire, MC | 1 |
| Frouin, V | 1 |
| Coulon, C | 1 |
| Fuseau, C | 1 |
| Hinnen, F | 1 |
| Dollé, F | 1 |
| Hantraye, P | 1 |
| Bottlaender, M | 1 |
| Thobois, S | 1 |
| Guillouet, S | 1 |
| Broussolle, E | 1 |
| Loos, D | 1 |
| Halbhübner, K | 1 |
| Kehr, W | 1 |
| Herken, H | 1 |
| Kandel', EI | 1 |
| Iadgarov, IS | 1 |
| Janzik, HH | 1 |
| Ryzhkova, MN | 1 |
| Tarasova, LA | 1 |
| McLellan, CA | 1 |
| Cohen, RM | 1 |
| Mierau, J | 1 |
| Schingnitz, G | 1 |
| Widner, H | 2 |
| Tetrud, J | 1 |
| Rehncrona, S | 2 |
| Snow, B | 1 |
| Brundin, P | 2 |
| Gustavii, B | 1 |
| Björklund, A | 2 |
| Lindvall, O | 2 |
| Sawle, GV | 1 |
| Leenders, KL | 1 |
| Marsden, CD | 1 |
| Ichiya, Y | 1 |
| Hosokawa, S | 1 |
| Kuwabara, Y | 1 |
| Tahara, T | 1 |
| Fukumura, T | 1 |
| Kato, M | 1 |
| Masuda, K | 1 |
| Goto, I | 1 |
| Barrio, JR | 1 |
| Huang, SC | 1 |
| Melega, WP | 1 |
| Yu, DC | 1 |
| Hoffman, JM | 1 |
| Satyamurthy, N | 1 |
| Mazziotta, JC | 1 |
| Phelps, ME | 1 |
| Rosenberg, NL | 1 |
| Myers, JA | 1 |
| Martin, WR | 1 |
| Wolters, EC | 1 |
| Huang, CC | 1 |
| Clark, C | 1 |
| Peppard, RF | 1 |
| Okada, J | 1 |
| Chu, NS | 1 |
| Adam, MJ | 1 |
| Li, D | 1 |
| Chiueh, CC | 1 |
| Firnau, G | 1 |
| Burns, RS | 1 |
| Nahmias, C | 1 |
| Chirakal, R | 1 |
| Garnett, ES | 1 |
| Dumont, M | 1 |
| Lamarre, Y | 1 |
| Klawans, HL | 3 |
| Goetz, C | 1 |
| Westheimer, R | 1 |
| Steg, G | 1 |
| Vogt, M | 1 |
| Martin, WE | 1 |
| Resch, JA | 1 |
| Baker, AB | 1 |
| Shimomura, SK | 1 |
| Hornykiewicz, O | 1 |
| Atadzhanov, M | 1 |
| Glabb, J | 1 |
| Hübner, W | 1 |
| Glabb, S | 1 |
| Metzel, E | 1 |
| Brion, S | 1 |
| Guérin, R | 1 |
| Albert, E | 2 |
| Cernacek, J | 1 |
| Brezny, I | 1 |
| Jagr, J | 1 |
| Fischer, PA | 2 |
| Horst, WD | 1 |
| Pool, WR | 1 |
| Spiegel, HE | 1 |
| Strelkova, NI | 1 |
| Zeĭnalov, RK | 1 |
| Tret'iakova, KA | 2 |
| Samoĭlova, ZT | 3 |
| Cincă, I | 1 |
| Bulandra, R | 1 |
| Serbănesco, A | 1 |
| Ninosu, N | 1 |
| Schneider, E | 1 |
| Jacobi, P | 1 |
| Maxion, H | 1 |
| Presthus, J | 1 |
| Stoliarova, LG | 1 |
| Kistenev, BA | 1 |
| Ballivet, J | 1 |
| Marin, A | 1 |
| Gisselmann, A | 1 |
| Khaliutina, LV | 1 |
| Lieberman, AN | 1 |
| Gauthier, G | 1 |
| Juge, O | 1 |
| Birchler, A | 1 |
| Shavolina, VA | 1 |
| Degkwitz, R | 2 |
| Ringel, SP | 1 |
| Guggenheim, MA | 1 |
| Couch, JR | 1 |
| Weinberg, W | 1 |
| Kimura, N | 1 |
| Tsukue, I | 1 |
| Cotzias, GC | 1 |
| Bruno, A | 1 |
| Bruno, SC | 1 |
| Hornykiewicz, OD | 1 |
| Hippius, H | 1 |
| Logemann, G | 1 |
| Gjerris, F | 1 |
| Oehme, P | 1 |
| Schwarz, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Dopamine Transporter Ligand [18F]FECNT[NCT00083629] | Phase 1 | 30 participants | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for dihydroxyphenylalanine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome.
Topics: Antiparkinson Agents; Blood Glucose; Carbidopa; Contrast Media; Deoxyglucose; Dihydroxyphenylalanine | 1995 |
[Type II Charcot-Marie-Tooth and dopa-sensitive Parkinson disease].
Topics: Charcot-Marie-Tooth Disease; Dihydroxyphenylalanine; Humans; Male; Middle Aged; Parkinson Disease, S | 1994 |
[Functional neurosurgery with an implantable and programmable pulse-generator: control of involuntary movement disorders].
Topics: Brain; Dihydroxyphenylalanine; Electric Stimulation; Electrodes, Implanted; Humans; Movement Disorde | 1997 |
Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
Topics: Aging; Animals; Antiparkinson Agents; Basal Ganglia; Brain Tissue Transplantation; Cell Transplantat | 2001 |
Pathophysiology of schizophrenia and the striatum.
Topics: Adult; Amphetamine; Animals; Basal Ganglia; Catalepsy; Caudate Nucleus; Dihydroxyphenylalanine; Dopa | 1972 |
Pathological aspects on Parkinson's syndrome.
Topics: Animals; Basal Ganglia; Basal Ganglia Diseases; Central Nervous System; Chlorpromazine; Corpus Stria | 1972 |
Drug-induced changes in brain dopamine and their relation to parkinsonism.
Topics: Animals; Basal Ganglia; Brain; Cerebral Ventricles; Dihydroxyphenylalanine; Dopamine; Electric Stimu | 1970 |
Biochemical and pharmacological aspects of Parkinsonism.
Topics: Animals; Blood-Brain Barrier; Brain; Central Nervous System; Chemoreceptor Cells; Chlorpromazine; Co | 1972 |
The pharmacology of parkinsonism (a review).
Topics: Acetylcholine; Animals; Atropa belladonna; Atropine; Central Nervous System; Chlorpromazine; Dextroa | 1968 |
Dopamine and extrapyramidal motor function and dysfunction.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Butyrophenones; Caudate Nucleus; Dihydroxyphenylalanin | 1972 |
[Hereditary aspects of Parkinson's disease (review of the literature)].
Topics: Adolescent; Adult; Aged; Catecholamines; Child; Dihydroxyphenylalanine; Diseases in Twins; Female; G | 1973 |
[Treatment of Parkinson's syndrome using L-dopa. 2].
Topics: Adult; Aged; Arrhythmias, Cardiac; Dihydroxyphenylalanine; Electrocardiography; Electromyography; Ha | 1973 |
Parkinson's syndrome--modern therapy, known facts and unanswered questions.
Topics: Brain; Brain Stem; Chemical Phenomena; Chemistry; Dihydroxyphenylalanine; Dopamine; Extrapyramidal T | 1973 |
[Therapy of Parkinsonian syndrome using L-dopa. Current state and problems].
Topics: Administration, Oral; Basal Ganglia Diseases; Carboxy-Lyases; Depression; Dihydroxyphenylalanine; Dr | 1974 |
[l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
Topics: Acetylcholine; Basal Ganglia; Butyrophenones; Chorea; Dihydroxyphenylalanine; Dopamine; Extrapyramid | 1969 |
[Therapy and problems of parkinsonism].
Topics: Adult; Aged; Amantadine; Animals; Antidepressive Agents; Apomorphine; Brain Chemistry; Brain Stem; D | 1971 |
4 trials available for dihydroxyphenylalanine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Caudate Nucleus; Corpus Striatum; Dihydroxyphen | 1992 |
[Combination of L-dopa and sulpiride in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Interactions; Dru | 1973 |
Stabilographic evaluation of dopaminergic and anticholinergic treatment of parkinsonism.
Topics: Adult; Aged; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Synergism; Humans; Middle Aged; | 1973 |
Effects of L-DOPA on pharmacological parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Haloper | 1966 |
62 other studies available for dihydroxyphenylalanine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The role of exposure to pesticides in the etiology of Parkinson's disease: a
Topics: Aged; Austria; Cohort Studies; Dihydroxyphenylalanine; Environmental Exposure; Female; Humans; Israe | 2019 |
Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Topics: Animals; Brain; Carbidopa; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Dopa | 2016 |
Comparative assessment of 6-[
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dihydroxyphenylalanine; Disease Models, | 2017 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carot | 2011 |
Cortical stimulation evokes abnormal responses in the dopamine-depleted rat basal ganglia.
Topics: Action Potentials; Animals; Basal Ganglia; Cerebral Cortex; Dihydroxyphenylalanine; Male; Motor Acti | 2011 |
"On-off" phenomenon in Parkinson's disease: correlation to the concentration of dopa in plasma.
Topics: Aged; Amino Acids; Blood-Brain Barrier; Brain; Dihydroxyphenylalanine; Female; Humans; Levodopa; Mal | 1984 |
[Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
Topics: Adult; Aged; Aged, 80 and over; Corpus Striatum; Dihydroxyphenylalanine; Dominance, Cerebral; Dopami | 1994 |
Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopa | 1994 |
Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Aged; Aged, 80 and over; Corpus Striatum; Dihyd | 1994 |
6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Catechols; Dihydroxyphenylalanine; Fluorine Radioi | 1993 |
Clinical heterogeneity of dopa-responsive dystonia: PET observations.
Topics: Adult; Aged; Corpus Striatum; Diagnosis, Differential; Dihydroxyphenylalanine; Dystonia; Female; Hum | 1993 |
PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). Case report.
Topics: Corpus Striatum; Dihydroxyphenylalanine; Dystonia; Female; Humans; Japan; Levodopa; Middle Aged; Neu | 1993 |
Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study.
Topics: Adult; Aged; Animals; Caudate Nucleus; Dihydroxyphenylalanine; Dopamine; Dopamine Antagonists; Femal | 1993 |
Striatal glucose metabolism and [18F]fluorodopa uptake in a patient with tumor-induced hemiparkinsonism.
Topics: Blood Glucose; Corpus Striatum; Dihydroxyphenylalanine; Dominance, Cerebral; Dopamine; Electromyogra | 1993 |
The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease.
Topics: Animals; Carbidopa; Carbon Isotopes; Carrier Proteins; Cerebellum; Dihydroxyphenylalanine; Disease M | 1996 |
Preservation of autoreceptor-mediated increases in dopamine synthesis in aged mice with experimentally-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Aromat | 1997 |
In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
Topics: 3T3 Cells; Animals; Antioxidants; Antiparkinson Agents; Apomorphine; Behavior, Animal; Biopterins; C | 1998 |
6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Chromatography, High Pressure Liquid; Corpus | 1998 |
Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment.
Topics: Antibodies, Monoclonal; Bone Marrow Transplantation; Dihydroxyphenylalanine; Fluorine Radioisotopes; | 1998 |
Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys.
Topics: Animals; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine Agents; Fluorine Radioisotopes; Levo | 1999 |
Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Carbon Radioisotopes; | 2001 |
Action of dopamine agonists on parkinson-like muscle rigidity induced by 6-aminonicotinamide.
Topics: 6-Aminonicotinamide; Animals; Brain Chemistry; Corpus Striatum; Diencephalon; Dihydroxyphenylalanine | 1979 |
[Catecholamine excretion and treatment of parkinsonism with midantan].
Topics: Adult; Aged; Amantadine; Catecholamines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female; Huma | 1976 |
[Drug-induced extrapyramidal symptoms].
Topics: Anticonvulsants; Antidepressive Agents; Antihypertensive Agents; Basal Ganglia Diseases; Contracepti | 1975 |
[Pathogenesis and treatment of manganese induced Parkinsonism].
Topics: Adult; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Manganese Poisoning; Norepinephrine; | 1975 |
Positron emission tomography with 18F-dopa: interpretation and biological correlates in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Cerebral Cortex; Corpus Striatum; | 1992 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Do | 1992 |
Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Brain Tissue Transplantation; Caudate Nucleus; Dihydro | 1992 |
Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.
Topics: Adolescent; Adult; Aged; Blood Glucose; Brain Mapping; Corpus Striatum; Diagnosis, Differential; Dih | 1991 |
Detection of preclinical Parkinson's disease with PET.
Topics: Adult; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Diseases in Twins; Dopamine; Female | 1991 |
Detection of preclinical Parkinson's disease with PET.
Topics: Adult; Caudate Nucleus; Corpus Striatum; Dihydroxyphenylalanine; Diseases in Twins; Dopamine; Female | 1991 |
6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Dihydroxyphenylalanin | 1990 |
Cyanide-induced parkinsonism: clinical, MRI, and 6-fluorodopa PET studies.
Topics: Cyanides; Dihydroxyphenylalanine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson D | 1989 |
Positron emission tomography in manganese intoxication.
Topics: Adult; Brain; Chronic Disease; Dihydroxyphenylalanine; Humans; Magnetic Resonance Imaging; Manganese | 1989 |
Determination and visualization of damage to striatal dopaminergic terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by [18F]-labeled 6-fluoro-L-dopa and positron emission tomography.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dihydroxyphenylalanine; Maca | 1987 |
Experimental tremor following CNS lesions in monkeys.
Topics: Animals; Cerebellar Nuclei; Dihydroxyphenylalanine; Disease Models, Animal; Haplorhini; Mesencephalo | 1973 |
Basic concepts underlying recent developments in the field of Parkinson's disease.
Topics: Biogenic Amines; Brain; Dihydroxyphenylalanine; Disease Models, Animal; Humans; Parkinson Disease; P | 1971 |
Juvenile parkinsonism.
Topics: Adult; Age Factors; Aged; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine; Humans; Male; M | 1971 |
Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Histamine H1 Antagonists; Humans; Parasympatholytics; Parkinson | 1972 |
[Surgical management of parkinsonism].
Topics: Age Factors; Basal Ganglia; Brain; Caudate Nucleus; Cerebellar Nuclei; Corpus Striatum; Dihydroxyphe | 1974 |
Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Blepharoptosis; Brain; | 1973 |
[Correlation of biochemical findings and the state of the neuromuscular apparatus in patients with parkinsonism during use of decimeter wave therapy].
Topics: Adult; Aged; Dihydroxyphenylalanine; Dopamine; Electromagnetic Phenomena; Electromyography; Epinephr | 1973 |
[The reserpine model of parkinsonism and changes in the metabolism of mediators].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine; Epinephrine; Male; Norepin | 1973 |
[Current medical treatment of Parkinsonian syndromes].
Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dihydroxyphenylalanine; Drug Combination | 1973 |
[Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
Topics: Aged; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Combinations; Female; Humans; Hyperkinesis; Male; | 1973 |
[The Parkinson syndrome].
Topics: Acetylcholine; Amino Acids; Dihydroxyphenylalanine; Dopamine; Humans; Parkinson Disease, Secondary | 1973 |
[Treatment of parkinsonism with the drug L-DOPA].
Topics: Brain Diseases; Dihydroxyphenylalanine; Hepatolenticular Degeneration; Humans; Movement Disorders; P | 1973 |
[Aspects of hypersexuality observed in parkinsonian patients treated by L-dopa].
Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Gonadal Steroid Hormones; Humans; Hypothalamo-Hypophyse | 1973 |
[Effect of l-dopa on the development of reserpine parkinsonism and the metabolism of catecholamines in rats].
Topics: Animals; Brain Chemistry; Catecholamines; Dihydroxyphenylalanine; Drug Interactions; Male; Parkinson | 1973 |
Parkinson's disease: a clinical review.
Topics: Adult; Aged; Brain Diseases; Bulbar Palsy, Progressive; Dementia; Diagnosis, Differential; Dihydroxy | 1974 |
Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Blood Pressure; Decarboxylation; Depression; Depressio | 1974 |
[Changes of catecholamine metabolism and symptoms of parkinsonism in rats with manganotoxicosis].
Topics: Animals; Brain; Catecholamines; Chlorides; Dihydroxyphenylalanine; Dopamine; Epinephrine; Male; Mang | 1974 |
[Drug-induced Parkinson's syndrome].
Topics: Acetylcholinesterase; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Humans; Movement Disor | 1972 |
Carbon monoxide-induced Parkinsonism.
Topics: Carbon Monoxide Poisoning; Dihydroxyphenylalanine; Electroencephalography; Humans; Male; Middle Aged | 1972 |
Motor dysfunction as a permanent complication of methanol ingestion. Presentation of a case with a beneficial response to levodopa treatment.
Topics: Adolescent; Dihydroxyphenylalanine; Female; Humans; Methanol; Motor Cortex; Movement Disorders; Opti | 1971 |
L-DOPA therapy in drug-induced parkinsonism evaluated by the method measuring the facial expression.
Topics: Adult; Dihydroxyphenylalanine; Facial Expression; Female; Humans; Male; Movement; Parkinson Disease; | 1971 |
Levodopa in the treatment of Parkinsonism.
Topics: Animals; Apomorphine; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Dihydroxyphenylalanine; D | 1971 |
Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future.
Topics: Animals; Brain; Dihydroxyphenylalanine; Dopamine; Humans; Injections, Intraperitoneal; Injections, I | 1970 |
[Effect of dioxyphenylalanine (L-DOPA) on extrapyramidal motoric hyperkineses after prolonged neuroleptic therapy].
Topics: Depression, Chemical; Dihydroxyphenylalanine; Drive; Emotions; Extrapyramidal Tracts; Female; Humans | 1970 |
Transitory procaine-induced Parkinsonism.
Topics: Chronic Disease; Dihydroxyphenylalanine; Female; Humans; Middle Aged; Parkinson Disease; Parkinson D | 1971 |
Differentiation of tardive dyskinesias and drug-induced Parkinsonism.
Topics: Amantadine; Diagnosis, Differential; Dihydroxyphenylalanine; Humans; Hyperkinesis; Movement Disorder | 1971 |
[Etiology and therapy of Parkinson's syndrome and related pharmacological concepts shown in experimental models].
Topics: Animals; Brain Chemistry; Chlorpromazine; Dihydroxyphenylalanine; Dopamine; Humans; Hypothermia; Mic | 1966 |